|
Market Closed -
Nasdaq
04:00:00 2026-11-12 pm EST
|
5-day change | 1st Jan Change | ||
| 0.8270 USD | -8.12% |
|
-24.13% | -39.64% |
| Nov. 09 | Allogene Therapeutics, Inc. - Special Call | |
| Nov. 09 | Allogene Therapeutics Reports First Clinical Data From Phase 1 RESOLUTION Study Of ALLO-329 In Autoimmune Disease | CI |
| Market Cap | 287M 259M 239M 216M 409M 26.94B 421M 2.87B 1.14B 14.4B 1.08B 1.05B 45.84B | P/E 2026 * |
-1.37x | P/E 2027 * | -1.28x |
|---|---|---|---|---|---|
| Enterprise Value | 44.44M 40.19M 37.1M 33.58M 63.36M 4.18B 65.26M 445M 177M 2.23B 167M 163M 7.11B | EV / Sales 2026 * |
10.7x | EV / Sales 2027 * | 12.3x |
| Free-Float |
89.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ALLO | Delayed | |
CBOE
| ALLO | Real-time |
Last Transcript: Allogene Therapeutics, Inc.
| 1 day | -8.12% | ||
| 1 week | -24.13% | ||
| Current month | -29.92% | ||
| 1 month | -40.93% | ||
| 3 months | -60.05% | ||
| 6 months | -64.04% | ||
| Current year | -39.64% |
| 1 week | 0.82 |  | 1.1 |
| 1 month | 0.82 | | 1.38 |
| Current year | 0.82 | | 4.46 |
| 1 year | 0.82 | | 4.46 |
| 3 years | 0.82 | | 5.78 |
| 5 years | 0.82 | | 19.52 |
| 10 years | 0.82 | | 55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zachary Roberts
CEO | Chief Executive Officer | 48 | 2026-06-30 |
Benjamin Beneski
CTO | Chief Tech/Sci/R&D Officer | 49 | 2025-02-27 |
Earl Douglas
CMP | Compliance Officer | 63 | 2023-08-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Arie Belldegrun
CHM | Chairman | 76 | 2017-10-31 |
David Chang
BRD | Director/Board Member | 66 | 2018-05-31 |
Joshua Kazam
BRD | Director/Board Member | 49 | 2017-10-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/21/26 | Sell | Chief Financial Officer | -36,342 | 0.0105% | ||
| 8/21/26 | Sell | Compliance Officer | -29,697 | 0.0086% | ||
| 7/1/26 | Free | Chief Executive Officer | 610,720 | 0.1769% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.12% | -24.13% | -32.76% | -66.92% | 287M | |
| +1.10% | -2.67% | +62.79% | +70.47% | 68.45B | |
| +0.45% | +9.17% | +15.84% | +93.57% | 61.31B | |
| -0.30% | +0.12% | +20.20% | +97.91% | 55.73B | |
| -0.96% | +7.41% | +10.20% | +108.91% | 47.51B | |
| -1.25% | +2.35% | +22.74% | +38.34% | 44.68B | |
| -2.41% | -0.73% | +167.89% | +794.72% | 38.14B | |
| +1.21% | -2.56% | +20.27% | +52.81% | 35.85B | |
| -1.93% | -1.70% | +76.48% | +53.54% | 33.05B | |
| -2.22% | +8.56% | -39.26% | +397.14% | 25.9B | |
| Average | -1.44% | -0.01% | +32.44% | +164.05% | 41B | |
| Weighted average by Cap. | -0.46% | +2.82% | +40.22% | +163.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.16M 3.76M 3.47M 3.14M 5.93M 391M 6.11M 41.7M 16.57M 209M 15.62M 15.29M 666M | 11.68M 10.56M 9.75M 8.82M 16.65M 1.1B 17.15M 117M 46.49M 587M 43.82M 42.89M 1.87B |
| Net income | -192M -173M -160M -145M -273M -18.02B -282M -1.92B -763M -9.64B -720M -704M -30.67B | -232M -210M -194M -175M -331M -21.8B -341M -2.32B -923M -11.65B -870M -852M -37.1B |
| Net Debt | -242M -219M -202M -183M -345M -22.76B -356M -2.43B -964M -12.17B -909M -889M -38.73B | -143M -129M -119M -108M -204M -13.43B -210M -1.43B -569M -7.18B -536M -525M -22.86B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-12 | $0.8270 | -8.12% | 10,687,592 |
| 26-11-11 | $0.9001 | -3.41% | 15,369,383 |
| 26-11-10 | $0.9319 | -12.08% | 22,865,240 |
| 26-11-09 | $1.060 | +1.92% | 10,768,824 |
| 26-11-06 | $1.040 | -4.59% | 12,625,093 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ALLO Stock
Select your edition
All financial news and data tailored to specific country editions
